These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

154 related items for PubMed ID: 2555366

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Purification of the Epstein-Barr virus/C3d complement receptor of human B lymphocytes: antigenic and functional properties of the purified protein.
    Nemerow GR, Siaw MF, Cooper NR.
    J Virol; 1986 May; 58(2):709-12. PubMed ID: 2422399
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Evidence for multiple sites of interaction in C3 for complement receptor type 2 (C3d/EBV receptor, CD21).
    Esparza I, Becherer JD, Alsenz J, De la Hera A, Lao Z, Tsoukas CD, Lambris JD.
    Eur J Immunol; 1991 Nov; 21(11):2829-38. PubMed ID: 1834472
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Human lymphocytes shed a soluble form of CD21 (the C3dg/Epstein-Barr virus receptor, CR2) that binds iC3b and CD23.
    Frémeaux-Bacchi V, Bernard I, Maillet F, Mani JC, Fontaine M, Bonnefoy JY, Kazatchkine MD, Fischer E.
    Eur J Immunol; 1996 Jul; 26(7):1497-503. PubMed ID: 8766552
    [Abstract] [Full Text] [Related]

  • 30. Identification of three gp350/220 regions involved in Epstein-Barr virus invasion of host cells.
    Urquiza M, Lopez R, Patiño H, Rosas JE, Patarroyo ME.
    J Biol Chem; 2005 Oct 21; 280(42):35598-605. PubMed ID: 16087675
    [Abstract] [Full Text] [Related]

  • 31. Mapping of the C3d ligand binding site on complement receptor 2 (CR2/CD21) using nuclear magnetic resonance and chemical shift analysis.
    Kovacs JM, Hannan JP, Eisenmesser EZ, Holers VM.
    J Biol Chem; 2009 Apr 03; 284(14):9513-20. PubMed ID: 19164292
    [Abstract] [Full Text] [Related]

  • 32. Structure and function of the B-lymphocyte Epstein-Barr virus/C3d receptor.
    Nemerow GR, Moore MD, Cooper NR.
    Adv Cancer Res; 1990 Apr 03; 54():273-300. PubMed ID: 2136962
    [No Abstract] [Full Text] [Related]

  • 33. How Epstein-Barr virus envelope glycoprotein gp350 tricks the CR2? A molecular dynamics study.
    Bingöl EN, Taştekil I, Yay C, Keskin N, Ozbek P.
    J Mol Graph Model; 2022 Jul 03; 114():108196. PubMed ID: 35500362
    [Abstract] [Full Text] [Related]

  • 34. Interaction between Epstein-Barr virus and a T cell line (HSB-2) via a receptor phenotypically distinct from complement receptor type 2.
    Hedrick JA, Watry D, Speiser C, O'Donnell P, Lambris JD, Tsoukas CD.
    Eur J Immunol; 1992 May 03; 22(5):1123-31. PubMed ID: 1315687
    [Abstract] [Full Text] [Related]

  • 35. Binding of the endogenously expressed Epstein-Barr virus (EBV) envelope glycoprotein gp350 with the viral receptor masks the major EBV-neutralizing epitope and affects gp350-specific ADCC.
    Khyatti M, Ahmad A, Blagdon M, Frade R, Menezes J.
    J Leukoc Biol; 1998 Aug 03; 64(2):192-7. PubMed ID: 9715258
    [Abstract] [Full Text] [Related]

  • 36. Analysis of epitope expression and the functional repertoire of recombinant complement receptor 2 (CR2/CD21) in mouse and human cells.
    Carel JC, Frazier B, Ley TJ, Holers VM.
    J Immunol; 1989 Aug 01; 143(3):923-30. PubMed ID: 2473114
    [Abstract] [Full Text] [Related]

  • 37. Tracing uptake of C3dg-conjugated antigen into B cells via complement receptor type 2 (CR2, CD21).
    Hess MW, Schwendinger MG, Eskelinen EL, Pfaller K, Pavelka M, Dierich MP, Prodinger WM.
    Blood; 2000 Apr 15; 95(8):2617-23. PubMed ID: 10753842
    [Abstract] [Full Text] [Related]

  • 38. Structure-guided identification of C3d residues essential for its binding to complement receptor 2 (CD21).
    Clemenza L, Isenman DE.
    J Immunol; 2000 Oct 01; 165(7):3839-48. PubMed ID: 11034390
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.